vimarsana.com

Page 4 - மையம் க்கு ஆரோக்கியம் தொழில்நுட்பம் மதிப்பீடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NICE backs selective internal radiation therapy for advanced liver cancer

NICE backs selective internal radiation therapy for advanced liver cancer 2nd March 2021 The UK’s National Institute for Health and Care Excellence (NICE) has recommended selective internal radiation therapy (SIRT) for the treatment of advanced liver cancer in final draft guidance. NICE’s draft guidance recommends the use of SIR-Spheres – made by SIRTEX – and TheraSphere – made by Boston Scientific – for treating advanced liver cancer that can’t be removed surgically and when transarterial therapy is not appropriate. The recommendation also specifies that these two therapies should only be considered for people with Child-Pugh grade A liver impairment. Despite limited clinical trial data for SIRTs compared with other treatment options, NICE’s appraisal committee concluded that SIRT may have fewer and more manageable side effects compared to systemic therapy sorafenib.

NICE recommends routine funding for Novartis Kisqali

NICE recommends routine funding for Novartis’ Kisqali 26th February 2021 The UK’s National Institute for Health and Care Excellence (NICE) has recommended routine access to Novartis’ Kisqali in certain advanced breast cancer patients. NICE’s draft guidance recommends Kisqali (ribociclib) in combination with fulvestrant for the treatment of locally advanced or metastatic breast cancer that is hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative. It will be routinely available on the NHS for adults who have had previous endocrine therapy and where exemestane plus everolimus is the most appropriate alternative treatment. Kisqali is taken as a once-daily pill and belongs to a class of drugs known as cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.